Tanzania recently reported its first two mpox cases, raising the number of affected countries to 23, officials from the ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Bethesda, Maryland Saturday, March 15, 2025, 10:00 Hrs [IST] ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

The first Mpox case in Nakasongola District was reported on September 9, 2024, in Zengebe Village, Lwampanga Town Council, ...

Six weeks after Rwanda-backed rebels captured the eastern Congolese cities of Goma and Bukavu, the region is facing a setback ...

“The high transmittance rate of the clade 1a Mpox variant is likely due to mutations the virus has picked up – exactly how these impact transmission isn’t currently clear and more research ...

Uganda is set to receive 100,000 doses of the Mpox vaccine to administer booster shots to those previously vaccinated, as well as high-risk individuals. This comes as the country continues ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...